These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1674150)

  • 1. [Dynamics of thyrostimulating immunoglobulin levels during treatment of diffuse toxic goiter].
    Sviridenko NIu; Mkrtukova NA; Kraĭnova SI; Nefedov SB; Kandror VI
    Probl Endokrinol (Mosk); 1991; 37(1):15-7. PubMed ID: 1674150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of merkazolyl on the level of thyrostimulating immunoglobulins of the blood in patients with diffuse toxic goiter].
    Oleĭnik VA; Khalangot ND
    Probl Endokrinol (Mosk); 1989; 35(1):32-5. PubMed ID: 2717572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibodies to the plasma membranes of thyrocytes in patients with diffuse toxic goiter during treatment with mercazole].
    Saarma VA; Podar TU
    Probl Endokrinol (Mosk); 1988; 34(5):17-9. PubMed ID: 3217382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of thyroid-stimulating immunoglobulins and thyrotropin-releasing hormone responsiveness in women with euthyroid goiter.
    Smyth PP; Neylan D; O'Donovan DK
    J Clin Endocrinol Metab; 1983 Nov; 57(5):1001-6. PubMed ID: 6137491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of mercasolyl on immunologic indicators in patients with diffuse toxic goiter].
    Epishin AV; Solomko LD; Epishina NA; Kuz'mich IuP
    Vrach Delo; 1989 Feb; (2):11-4. PubMed ID: 2711649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
    Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience using lithium carbonate in the complex treatment of diffuse toxic goiter].
    Petrov NM
    Ter Arkh; 1985; 57(12):32-6. PubMed ID: 3937256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid-stimulating hormone levels in idiopathic euthyroid goiter.
    Young RL; Harvey WC; Mazzaferri EL; Reynolds JC; Hamilton CR
    J Clin Endocrinol Metab; 1975 Jul; 41(1):21-6. PubMed ID: 1150864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Certain problems of pathogenesis of diffuse non-toxic sporadic goiter].
    Potin VV; Tarasova OV; Shliakhtina LG
    Probl Endokrinol (Mosk); 1974; 20(6):27-31. PubMed ID: 4141506
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of phytotherapy for treatment of thyroid diseases].
    Kvacheniuk AN; Kvacheniuk EL
    Lik Sprava; 2012; (3-4):99-104. PubMed ID: 23356147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of goiter treatment with L-thyroxine in patients over 40].
    Wollmann B; Meller J; Hüfner M; Becker W
    Nuklearmedizin; 1998 Jan; 37(1):41-4. PubMed ID: 9467169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.